Blau Farmacêutica (BLAU3) Q3 2025 earnings summary

Executive summary

• Net revenue reached BRL 475 million in 3Q25, stable year-over-year, with the Aesthetics segment as a highlight and 11% growth in new product launches; Hospital segment impacted by capacity constraints and lower public channel sales.

• Gross margin improved for the eighth consecutive quarter, reaching 41% (40.6% in some reports), driven by the Bergamo turnaround, operational efficiencies, and favorable sales mix.

• Net income rose 52% year-over-year to BRL 106 million, mainly due to operational gains and BRL 60 million in FX and interest from the Prothya divestment; recurring net income was BRL 72 million, up 5%.

• Major investments in capacity expansion and R&D, with CAPEX of BRL 117 million, up 68% year-over-year.

• Strategic advances include new production lines, expansion of the Aesthetics business, and progress in monoclonal antibody development.

Financial highlights

• Net revenue: BRL 475 million for 3Q25 (stable year-over-year); Aesthetics BU up 42% year-over-year.

• Gross margin: 41% (40.6% in some reports), up 110 bps year-over-year; 42% excluding BRL 8 million provision.

• Recurring EBITDA: BRL 114 million (24.1% margin), up 52% year-over-year; margin would be 25.8% excluding Hemarus provision.

• Net income: BRL 106 million (22.2% margin), up 52% year-over-year; recurring net income: BRL 72 million (15.2% margin), up 5%.

• Net debt: BRL 197 million, leverage at 0.4x EBITDA; cash covers 62% of scheduled amortizations through 2028.

Outlook and guidance

• Production capacity set to expand by at least 70% by 2026–2028, with new lines and efficiency measures coming online.

• New launches and regulatory approvals expected to drive growth, with BRL 3.0 billion in products submitted to ANVISA for launch by 2027.

• Margins expected to exceed historical values as new investments and international expansion materialize.

• Prothya divestment proceeds (EUR 52.1 million) to be recognized in 4Q25, strengthening cash position.